Not until the middle of the twentieth century was there a recognizable clinical label for the range of developmental differences now grouped under Autism Spectrum Disorder. The American Psychiatric Association replaced the separate DSM-IV diagnoses (Autistic Disorder, Asperger’s Disorder, and PDD-NOS) with a single diagnosis, Autism Spectrum Disorder (ASD), in the DSM‑5 (2013). The DSM‑5 frames ASD as a single spectrum with specifiers for language level, intellectual ability, and the level of support required rather than separate categorical disorders.

What is Autism Spectrum Disorder (ASD)?

Autism spectrum disorder is a neurodevelopmental condition defined by differences in social communication and interaction, together with restricted, repetitive patterns of behavior, interests, or activities. These features occur along a continuum, ranging from individuals who require substantial support to those who are relatively independent but experience social-communication challenges.

All children with ASD demonstrate deficits in 1) social interaction, 2) verbal and nonverbal communication, and possibly demonstrate 3) repetitive behaviors or interests. Additionally, they will often exhibit unusual responses to sensory experiences, such as specific sounds or the appearance of objects. Each of these symptoms ranges from mild to severe. They will present differently in each individual. For instance, a child may have little trouble learning to read but exhibit extremely poor social interaction. Each child will display individualized communication, social, and behavioral patterns, but still fit into the overall diagnosis of ASD.

Conditions Historically Grouped under PDD

The older terms—Autistic Disorder, Asperger Syndrome, and PDD‑NOS—were consolidated under ASD in the DSM‑5. Individuals who previously had a diagnosis of Asperger syndrome or PDD‑NOS are now described with the single ASD diagnosis and appropriate specifiers (for example, “ASD, level 1, without intellectual impairment”). This change aims to provide clearer, more consistent diagnostic criteria, as well as to describe severity and support needs more directly.

Prevalence and Detection

Recent U.S. surveillance data indicate ASD is now identified in roughly 1 in 31 eight‑year‑old children in surveillance sites, reflecting both increased detection and broader recognition of the spectrum. ASD occurs across all racial, ethnic, and socioeconomic groups and is reported substantially more often in boys than girls (several-fold higher rates in males). Early identification is emphasized: standardized screening at 18 and 24 months is recommended for all children during well‑child visits, and earlier referral for evaluation is advised when concerns arise.

Early Signs and Parent Observations

Parents are often the first to notice developmental differences. Some children show atypical social responsiveness or limited interest in people from early infancy; others show a period of expected development followed by slowed progress or regression in social-communication skills between roughly 12 and 36 months.

Possible Indicators of Autism Spectrum Disorders

Does not babble, point, or make meaningful gestures by 12 months
Does not use single words by 16 months
Does not combine words by 24 months
Loss of previously acquired language or social skills at any age
Poor eye contact, limited social smiling, or unusual play patterns

If a caregiver or clinician observes these signs, timely referral for diagnostic evaluation and connection to early supports is recommended.

Common Features Across the Spectrum

People with ASD show variable profiles in social interaction, language, repetitive behaviors, and sensory processing. Some individuals have strong visual-spatial skills or unusually deep interests in specific topics, while others have intellectual disability and significant support needs. Emotional regulation differences, such as heightened anxiety or difficulties with flexibility and change, are frequent.

Diagnostic Framework and Evaluation

Diagnosis is made using a combination of standardized developmental screening and a comprehensive diagnostic evaluation. A two-stage approach is standard: routine screening during a well-child visit with a pediatrician, followed by multidisciplinary diagnostic assessment when screening or surveillance indicates risk.

Common tools used in structured diagnostic assessments include caregiver interviews and direct observation measures. Clinicians may use instruments designed to capture core ASD symptoms and developmental profile, and they typically evaluate for co‑occurring conditions (language delay, intellectual disability, seizures, genetic syndromes) and sensory differences.

Screening

A “well child” check-up should include a developmental screening test. If your child’s pediatrician does not routinely use such a test, ask that it be done. Your own observations and concerns about your child’s development will be essential in helping identify any issues your child my be displaying.

Professional organizations recommend developmental surveillance and universal ASD-specific screening at 18 and 24 months. When screening or parental concerns indicate possible ASD or developmental delay, clinicians should refer for diagnostic evaluation and begin early intervention services without waiting for a definitive ASD diagnosis.

Comprehensive Diagnostic Evaluation

The second stage of diagnosis will comprehensively identify if a child has ASD. This evaluation may be conducted by a multidisciplinary team that includes a psychologist, a neurologist, a psychiatrist, a speech therapist, or other professionals. Because ASD is a complex disorder and may involve other neurological or genetic problems, a comprehensive evaluation should entail a neurologic and genetic assessment, along with in-depth cognitive and language testing.7

Co-Occurring Medical and Developmental Conditions

Many conditions can co‑occur with ASD and should be considered during evaluation.

Intellectual disability: present at varying rates depending on the population studied; contemporary surveillance shows a greater proportion of children with ASD without co‑occurring intellectual disability than in earlier decades.
Seizure disorders: seizures affect a meaningful minority of people with ASD (estimates vary, often cited in the range of about 20–30%), and rates increase with age and with lower cognitive ability.
Fragile X Syndrome (FMR1): a known genetic cause of intellectual disability and a contributor in a small percentage of people with ASD; genetic testing is frequently recommended when ASD is diagnosed.
Tuberous sclerosis complex (TSC): a genetic condition associated with increased risk of ASD in a minority of cases.

Treatment Considerations

There is no single best treatment package for all children with ASD. One point that most professionals agree on is that early intervention is important; another is that most individuals with ASD respond well to highly structured, specialized programs. Before you make decisions on your child’s treatment, you will want to gather information about the various options available. Learn as much as you can, look at all the options, and make your decision on your child’s treatment based on your child’s needs. You can visit public schools in your area to see the types of programs they offer for children with ASD. Guidelines used by the Autism Society of America include the following questions parents can ask about potential treatments:

Will the treatment result in harm to my child?
How will failure of the treatment affect my child and family?
Has the treatment been validated scientifically?
Are there assessment procedures specified?
How will the treatment be integrated into my child’s current program?

The National Institute of Mental Health suggests a list of questions parents can ask when planning for their child:

How successful has the program been for other children?
How many children have gone on to placement in a regular school, and how have they performed?
Do staff members have training and experience in working with children and adolescents with autism?
How are activities planned and organized?
Are there predictable daily schedules and routines?
How much individual attention will my child receive?
How is progress measured?
Will my child’s behavior be closely observed and recorded?
Will my child be given tasks and rewards that are personally motivating?
Is the environment designed to minimize distractions?
Will the program prepare me to continue the therapy at home?
What is the cost, time commitment, and location of the program?

An effective treatment program will build on the child’s interests, offer a predictable schedule, teach tasks as a series of simple steps, actively engage the child’s attention in highly structured activities, and provide regular reinforcement of behavior.

Parental involvement has emerged as a major factor in treatment success. Parents work with professionals and therapists to identify the behaviors to be changed and the skills to be taught.

As soon as an individual has been identified as having ASD, interventions should begin to teach early communication and social interaction skills.

Intervention models supported by research include intensive behavioral interventions (e.g., applied behavior analysis, ABA) and Naturalistic Developmental Behavioral Interventions (NDBIs) such as the Early Start Denver Model (ESDM). Parent‑mediated interventions and family coaching are evidence-based approaches for improving communication and social engagement. Recent reviews emphasize the importance of individualized plans that combine developmental, behavioral, and educational strategies tailored to the child’s profile and family priorities.

Medications and Other Biological Treatments

Medications do not treat the core social‑communication features of ASD. However, pharmacologic treatments can address associated symptoms such as severe irritability, aggression, or mood symptoms.

Update (antipsychotics approved): Two atypical antipsychotics—risperidone and aripiprazole—are FDA‑approved to treat irritability (including aggression and self‑injurious behavior) associated with ASD in pediatric patients. These medications can reduce severe behavioral problems but carry potential side effects (weight gain, metabolic changes, sedation), so clinicians monitor patients closely and use the lowest effective dose for the shortest necessary duration.

Other classes of medications (antidepressants, stimulants, anticonvulsants) may be used judiciously to treat co‑occurring conditions such as anxiety, ADHD symptoms, or seizures. Medication decisions should be individualized and monitored carefully.

Educational and Transition Planning

Early and sustained access to appropriate educational services improves long‑term outcomes. In the United States, IDEA ensures access to special education and related services, with an Individualized Education Program (IEP) developed for school‑age children and an Individualized Family Service Plan (IFSP) for children under three.
Transition planning for adolescence and adulthood should begin early. Supported employment, vocational training, and varied living arrangements (including independent, supported, or group living) are options tailored to an individual’s abilities and support needs. Families are encouraged to explore Social Security, Medicaid waivers, and community supports early to plan for adulthood.

Biological and Genetic Research

Genetic research has advanced substantially. Large-scale genomic studies have identified numerous genes associated with ASD risk (for example, CHD8, SCN2A, SYNGAP1, and many others), supporting a model in which both rare, high‑impact variants and common, small‑effect variants contribute to risk. Ongoing large‑scale sequencing and functional studies are clarifying how diverse genetic differences converge on brain development pathways, including synapse function, chromatin remodeling, and neuronal excitability.
Neuroimaging and neuropathological studies suggest atypical early brain development in some children who develop ASD, including differences in growth rates of brain regions and altered connectivity. Research continues into how genetic susceptibilities interact with prenatal and early‑life environmental exposures to influence neurodevelopment.

Self-Advocacy, Communities, and Terminology

Language around ASD has evolved: many individuals prefer identity‑first language (“autistic person”), while others prefer person‑first (“person with autism”). Clinicians and families should respect individual preferences. Individuals with ASD and their families benefit from community support, self‑advocacy organizations, and evidence‑based resources.

Practical Recommendations for Caregivers

If you have concerns about your child’s development, discuss them with your pediatrician and request developmental screening.
Request ASD‑specific screening at 18 and 24 months, or sooner if concerns are present.
If screening is positive, seek a multidisciplinary evaluation and begin early interventions while diagnostic work is underway.
Consider evidence‑based behavioral and developmental interventions and seek programs that include parent training.
Collaborate with educators to develop appropriate IEP/IFSP goals and start transition planning early for adolescence and young adulthood.
Talk with your child’s healthcare team about medication only when symptoms significantly interfere with safety or daily function; review risks and benefits carefully.

References

1 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR (fourth edition, text revision). Washington DC: American Psychiatric Association, 2000.

2 Filipek PA, Accardo PJ, Baranek GT, Cook Jr. EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kellen RJ, Levy SE, Minshew NJ, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR. The screening and diagnosis of autism spectrum disorders. Journal of Autism and Developmental Disorders, 1999; 29(2): 439-484.

3 Newschaffer CJ (Johns Hopkins Bloomberg School of Public Health). Autism Among Us: Rising Concerns and the Public Health Response [Video on the Internet]. Public Health Training Network, 2003 June 20.

4 Volkmar FR. Medical Problems, Treatments, and Professionals. In: Powers MD, ed. Children with Autism: A Parent’s Guide, Second Edition. Bethesda, MD: Woodbine House, 2000; 73-74.

5 Powers MD. What Is Autism? In: Powers MD, ed. Children with Autism: A Parent’s Guide, Second Edition. Bethesda, MD: Woodbine House, 2000, 28.

6 Smalley SI, Autism and tuberous sclerosis. Journal of Autism and Developmental Disorders, 1998; 28(5): 407-414.

7 Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook Jr. EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin SW, Tuchman RF, Volkmar FR. Practice parameter: screening and diagnosis of autism. Neurology, 2000; 55: 468-479.

8 Baird G, Charman T, Baron-Cohen S, Cox A, Swettenham J, Wheelwright S, Drew A. A screening instrument for autism at 18 months of age: A 6-year follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry, 2000; 39: 694-702.

9 Robbins DI, Fein D, Barton MI, Green JA. The modified checklist for autism in toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders. Journal of Autism and Developmental Disorders, 2001; 31(2): 149-151.

10 Stone WL, Coonrod EE, Ousley OY. Brief report: screening tool for autism in two-year-olds (STAT): development and preliminary data. Journal of Autism and Developmental Disorders, 2000; 30(6): 607-612.

11 Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism Screening Questionnaire: diagnostic validity. British Journal of Psychiatry, 1999; 175: 444-451.

12 Ehlers S, Gillberg C, Wing L. A screening questionnaire for Asperger syndrome and other high-functioning autism spectrum disorders in school age children. Journal of Autism and Developmental Disorders, 1999; 29(2): 129-141.

13 Garnett MS, Attwood AJ. The Australian scale for Asperger’s syndrome. In: Attwood, Tony. Asperger’s Syndrome: A Guide for Parents and Professionals. London: Jessica Kingsley Publishers, 1997.

14 Scott FJ, Baron-Cohen S, Bolton P, Brayne C. The Cast (Childhood Asperger Syndrome Test): preliminary development of a UK screen for mainstream primary-school-age children. Autism, 2002; 2(1): 9-31.

15 Tadevosyan-Leyfer O, Dowd M, Mankoski R, Winklosky B, Putnam S, McGrath L, Tager-Flusberg H, Folstein SE. A principal components analysis of the autism diagnostic interview-revised. Journal of the American Academy of Child and Adolescent Psychiatry, 2003; 42(7): 864-872.

16 Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 2000; 30(3): 205-230.

17 Van Bourgondien ME, Marcus LM, Schopler E. Comparison of DSM-III-R and childhood autism rating scale diagnoses of autism. Journal of Autism and Developmental Disorders, 1992; 22(4): 493-506.

18 Department of Health and Human Services. Mental Health: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institute of Mental Health, 1999.

19 Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. Journal of Consulting and Clinical Psychology, 1987; 55: 3-9.

20 McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal on Mental Retardation, 1993; 97: 359-372.

21 Couper JJ, Sampson AJ. Children with autism deserve evidence-based intervention. Medical Journal of Australia, 2003; 178: 424-425.

22 American Academy of Pediatrics Committee on Children With Disabilities. The pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics, 2001; 107(5): 1221-1226.

23 Dunlap G, Foxe L. Teaching students with autism. ERIC EC Digest #E582, 1999 October.

24 Autism Society of America. Biomedical and Dietary Treatments (Fact Sheet) [cited 2004], 2003. Bethesda, MD: Autism Society of America.

25 McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 2003; 64 (supplement 4): 16-25.

26 Research Units on Pediatric Psychopharmacology Network. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 2002; 347(5): 314-321.

27 Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA, 2003; 290(13): 1763-1766.

28 Akshoomoff N, Pierce K, Courchesne E. The neurobiological basis of autism from a developmental perspective. Development and Psychopathology, 2002; 14: 613-634.

29 Korvatska E, Van de Water J, Anders TF, Gershwin ME. Genetic and immunologic considerations in autism. Neurobiology of Disease, 2002; 9: 107-125.

30 Courchesne E. Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA, 2003; 290(3): 337-344. NIH Publication No.04-5511
April 2004 Citation for this publication: Strock, Margaret (2004). Autism Spectrum Disorders (Pervasive Developmental Disorders). NIH Publication No. NIH-04-5511, National Institute of Mental Health, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD, 40 pp. https://www.nimh.nih.gov/publicat/autism.cfm